Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 乐普(北京)医疗器械股份有限公司是一家医疗器械制造企业,公司主要从事冠状动脉介入和先心病介入医疗器械的研发、生产和销售.公司主要产品包括用于冠心病治疗的血管内药物(雷帕霉素)洗脱支架系统、冠脉支架输送系统、PTCA球囊扩张导管、药物中心静脉导管等.公司在业内第一个获得国家药监局颁发的"冠状动脉支架输送系统"产品注册证(III类)、第一个研发并试制成功抗感染"药物中心静脉导管".公司拥有国家药监局颁发的III类医疗器械产品注册证9项,拥有北京药监局颁发的II类医疗器械产品注册证1项,拥有北京药监局颁发的I类医疗器械产品注册证2项.公司被认定为"北京市高新技术企业"、"中关村科技园区百家创新型试点企业"、"北京市市级企业技术中心",并成为中国医疗器械行业协会外科植入物专业委员会常务理事,2009年1月,公司被《福布斯》中文版评为"2009中国潜力企业"第三名;2009年3月,公司被评为"中关村20周年突出贡献企业单位"称号;2009年6月,公司荣获"北京市著名商标"。
Main Business 医疗器械及其配件的技术开发、生产，销售
Legal Representative 蒲忠杰
Top Executives
董事长：蒲忠杰
副董事长：王其红
董事：蒲绯,徐扬
独立董事：甘亮,王立华,曲新
Top 5 Shareholder
Shareholder name Nature Holding Date
中国船舶重工集团公司第七二五研究所（洛阳船舶材料研究所）流通A股12.98%30/09/2024
蒲忠杰限售股+流通A股12.13%30/09/2024
WP MEDICAL TECHNOLOGIES,INC限售股+流通A股6.59%30/09/2024
北京厚德义民投资管理有限公司流通A股3.60%30/09/2024
中国银行股份有限公司－华宝中证医疗交易型开放式指数证券投资基金流通A股2.35%30/09/2024
Company Secretary 江维娜
Solicitors 北京市中伦律师事务所
Auditors 立信会计师事务所（特殊普通合伙）
Tel No 010-80120622
Fax No 010-80120776
Website www.lepumedical.com
Email zqb@lepumedical.com
Company Address
Register: 北京市昌平区超前路37号
Office: 北京市昌平区超前路37号
Listing Date 30/10/2009
Shares Capital
Shares Capital: 1,880,611,005
Total A Share: 1,880,611,005
Listed A Share: 1,616,036,468
Non-tradable A Share: 264,574,537
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.676
DPS(RMB)* ¥ 0.331
NBV Per Share(RMB)* ¥ 8.381
Market Capitalization(RMB) 16.807B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.